Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.49 |
| ▸ | ICMT | O60725 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911623 | 0.90 | SLC9A1 (0.49) | SLC9A1ICMTHCAR3TDO2GRM2 | |
| SCHEMBL19911634 | 0.89 | SLC9A1 (0.44) | SLC9A1ICMTHCAR3PDE2AGRM2 | |
| SCHEMBL19911498 | 0.86 | SLC9A1 (0.50) | SLC9A1HCAR3TDO2CYP4Z1 | |
| SCHEMBL19911605 | 0.85 | SLC9A1 (0.49) | SLC9A1HCAR3TDO2CYP4Z1 | |
| SCHEMBL19915957 | 0.84 | SLC9A1 (0.46) | SLC9A1ICMTHCAR3PDE2ATDO2 | |
| SCHEMBL19848592 | 0.84 | SLC9A1 (0.62) | SLC9A1HCAR3TDO2GRM2 | |
| SCHEMBL19911528 | 0.83 | SLC9A1 (0.47) | SLC9A1HCAR3 | |
| SCHEMBL19915673 | 0.82 | SLC9A1 (0.46) | SLC9A1ICMTHCAR3TDO2 | |
| SCHEMBL19911447 | 0.82 | SLC9A1 (0.74) | SLC9A1GRM2CYP4Z1 | |
| SCHEMBL19911629 | 0.81 | SLC9A1 (0.60) | SLC9A1HCAR3TDO2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885ICMT 374/4885HCAR3 4636/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | SLC9A1 341/4885ICMT 374/4885HCAR3 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.